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all GERD patients. CONCLUSION: Partial responders to PPI
treatment are more costly and score lower on physical and
mental dimensions of HRQoL than patients responding well to
PPI treatment and GERD patients in general.
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OBJECTIVES: This study aims to examine whether the test-
retest reliability of SF-36, WHOQOL-BREF, and EQ-5D
questionnaires will be changed by different administration
approaches by which patients with chronic liver disease self-
report their quality of life. METHODS: Patients with chronic
liver disease were recruited from the outpatient department of a
medical centre in Taiwan. Their self-reported questionnaires
were collected by two approaches. The ﬁrst approach patients
received was an interview and questionnaire in hospital. They
returned the retest questionnaire by mail two weeks later. In the
second approach, patients were instructed to ﬁll out both test and
retest questionnaires at home and send back by two separate
mails. The time gap was also two weeks. After scoring question-
naires, a paired-t test was conducted to compare test-retest
reliability for three questionnaires. The mean score difference
between two approaches was examined by independent t test.
An analyses of mean score differences of different domains
were performed by multiple linear regressions. RESULTS: Of 69
patients recruited for the ﬁrst approach; 52 persons completed
both questionnaires (75%), while the response rate of the second
approach was 84% (127 of 151). The results indicate that there
is no statistically signiﬁcant difference in the test-retest reliability
of SF-36, WHOQOL-BREF, and EQ-5D questionnaires. There
was also no signiﬁcant difference in the test-retest results between
two approaches, except in the dimension ‘pain/discomfort’ mean
difference (0.3  1.2 and -0.1  1.1, p = 0.03) by EQ-5D.
Similar results (p = 0.04) were also found by multiple linear
regression, after controlling age, sex, and education. This reﬂects
that greater pain/discomfort was more likely to present in the
ﬁrst approach as compared to that in the second one. CONCLU-
SIONS: Alternative administration approaches did affect the
results of test-retest questionnaires, which idicated that the
Hawthorne Effect occurred in the interview in hospital.
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OBJECTIVE: Current GERD assessment questionnaires for
adults are limited in their ability to capture nocturnal symptoms.
The objective of this study was to develop and validate an instru-
ment to assess severity and impact of nocturnal GERD symp-
toms. METHODS: Two focus groups and 16 cognitive debrieﬁng
interviews were conducted among patients with GERD to iden-
tify key issues and concerns related to nocturnal GERD symp-
toms. The resulting 29-item draft instrument was included in a
study of 196 patients diagnosed with GERD at 12 clinics in the
United States to evaluate the psychometric properties. Assess-
ments were conducted at baseline and at 4 weeks. Construct
validity was evaluated using the Patient Assessment of Upper
Gastrointestinal Disorders Symptoms Questionnaire (PAGI-
SYM), Patient Assessment of Upper Gastrointestinal Disorders-
Quality of Life (PAGI-QOL), number of nights with symptoms,
disability days, and clinician and patient assessment of GERD
severity. Exploratory factor analyses and item response theory
analyses were conducted to ﬁnalize items and subscales.
RESULTS: Mean age of participants was 45 years; 76% were
female and 68% were Caucasian. Patient-rated severity at base-
line was mild or moderate for 69% of participants, with 48%
reporting GERD-related symptoms 2–3 nights within the past
week. The ﬁnal questionnaire includes 20 items and consists of 3
subscales: nocturnal symptoms; morning impact; and concern
regarding nocturnal GERD. The subscales demonstrated internal
consistency reliability (Cronbach’s alpha 0.92–0.95). The sub-
scale scores were statistically signiﬁcantly correlated with sub-
scales of the PAGI-SYM and PAGI-QOL (0.41–0.81; all
p < 0.0001), number of nights with GERD symptoms (0.45–
0.54; all p < 0.0001), disability days (0.19–0.43; all p < 0.05),
and clinician and patient-reported disease severity (0.46–0.72; all
p < 0.0001). CONCLUSION: Results support the reliability and
validity of the newly developed questionnaire as a measure of
severity of nocturnal GERD symptoms, morning impact, and
concern related to nocturnal GERD.
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OBJECTIVE: To determine the prevalence and severity of
constipation among persons receiving hospice care in the
United States, using longitudinal patient-reported outcomes.
METHODS: Data was obtained from excelleRx, Inc, a national
hospice pharmacy. Patient-reported symptom outcome data were
collected by telephone for each patient by trained research assis-
tants within the ﬁrst three days of hospice admission. Data
collection continued every three to four days until patients were
discharged, or unable or unwilling to report data or dead.
Patients rated constipation on a four-point verbal rating scale of
none, mild, moderate, and severe. The sample for our analysis
came from ﬁve participating hospices and included all discharged
or deceased patients receiving home hospice care with an admis-
sion assessment record and at least one subsequent telephone
assessment for constipation between April 1, 2006 and October
20, 2007. The ﬁrst patient reported constipation assessment
score post hospice admission was used to estimate prevalence
and severity of constipation. RESULTS: A total of 309 patients
met the inclusion criteria, the majority of which were female
(n = 167, 54%), Caucasian (n = 282, 91%), >65 years of age
(n = 238, 77%) and had a primary diagnosis of cancer (n = 223,
72%). All patients were prescribed opioid therapy during their
hospice experience. Constipation was reported at the ﬁrst assess-
ment post admission by 26% of the patients (n = 80), 28.7 % of
patients with cancer (n = 64) and 18.6% of patients without
cancer (n = 16). Most patients who reported constipation were
female (58.8%) and >65 years (78.8%). Constipation intensity
was rated as mild (n = 32; 40%), moderate (n = 23; 28.8%)
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and severe (n = 25; 31%). CONCLUSION: Constipation was
reported by approximately 25% of the hospice patients, a third
of whom rated their constipation as severe. A substantial number
of hospice patients may require aggressive management of con-
stipation. This information may be useful as a process indicator
of quality of care.
GASTROINTESTINAL DISORDERS—Health Care Use &
Policy Studies
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OBJECTIVE: Assess knowledge and care seeking behaviors
for gastro-esophageal reﬂux disease via a population-based
approach. Identify variations in knowledge, attitude, and care
seeking patterns between racial groups, while also investigating
socio-economic disparities. METHODS: A questionnaire based
upon previous work (Srinivansin, J Clin Gastro) was developed
to assess knowledge, attitudes, and care seeking patterns for
GERD and was translated into Chinese and Spanish. We worked
with community and faith-based leaders to identify events for
data collection. Four ethnic groups (White, Black, Asian, His-
panic) were compared. All descriptive and multivariate analyses
were done using SAS 9.1. RESULTS: Although Hispanics had the
highest prevalence rate for GERD, their familiarity with the
condition was lower (61.2%), compared to Whites (68.9%) and
Blacks (63.7%); Asians were the least familiar with GERD
(44.6%) (P < 0.0001). There was a positive correlation between
increased education level and awareness for GERD (P < 0.0001).
In general, Whites were the most likely to recognize GERD
symptoms and behaviors to control GERD, while Asians were
the least likely. Blacks and Hispanics were more likely to go to
the Emergency Room for severe heartburn compared to Asians
and Whites (P < 0.0001). Asians were least likely to go see a
doctor when presented with a complication of heartburn
(P < 0.0001). A total of 40.8% of Asians and 35.5% of Hispan-
ics indicated that cost and the lack of health insurance would
prevent them from seeing a doctor, higher rates than Whites and
Blacks (P = 0.0073). CONCLUSION: Minorities lack an equal
understanding of GERD, compared to Whites. Asians were par-
ticularly inaccurate in assessing symptoms for GERD and were
least likely to see a doctor. Further research should focus on
improving minority understanding of GERD symptoms and at
what point to consult a physician. The impact of cost and lack of
insurance on care seeking behaviors amongst Hispanics and
Asians should also be examined.
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OBJECTIVE: To examine pharmacy costs of a Prior Authoriza-
tion (PA) on lubiprostone for elderly chronic constipation (CC)
patients in a Medicare Part-D plan. METHODS: Cost impact of
PA was calculated by estimating annual pharmacy cost differ-
ences with PA (PA administration costs + medication costs) and
without PA (medication costs only). Model inputs included pub-
lished estimates of CC prevalence; lubiprostone utilization from
IMS Health, 2007; average PA approval rate, PA costs and
co-payment from payer interviews; and lubiprostone wholesale
acquisition costs. Annual medication costs in both scenarios
included costs and utilization of lubiprostone less co-payment,
assuming third-tier placement for lubiprostone. All previously
rejected prescriptions were assumed to be approved after lifting
PA, resulting in 21.24% increase in prescription volume. Sensi-
tivity analyses were performed on PA cost, PA approval rate,
and expected increase in prescription volume after lifting PA.
RESULTS: CC prevalence was 14.7%, of which 1.14% were
lubiprostone users. For a 1-million member plan, this resulted in
1264 PA requests costing $27 each. Annual cost of PA adminis-
tration was $34,130. PA approval rate for the elderly was 77.7%
(or 982 approved users). Average number of ﬁlls per person per
year was 3.8. A 30-day lubiprostone prescription costed $28.40
($86.40 WAC-$60 co-payment + $2 dispensing fee). Drug costs
were $105,997, resulting in total annual cost with PA of
$140,127. Total annual costs without PA were $128,506, based
on an additional 209 users, resulting in annual savings of
$11,621. Sensitivity analyses indicated break even scenarios from
removing PA on lubiprostone when cost per PA > $17.81 or PA
approval rate > 69.18%, or expected increase in prescriptions
from lifting PA < 32.20%. CONCLUSIONS: PA program for
lubiprostone offers no ﬁnancial savings to a Medicare plan based
on current approval rates and annual utilization for elderly
patients with CC in the base case as well as in sensitivity analyses.
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OBJECTIVE: To examine pharmacy costs of a Prior Authoriza-
tion (PA) restriction on lubiprostone for chronic constipation
(CC) patients in a commercial managed care plan. METHODS:
Cost impact of PA was calculated by estimating annual pharmacy
cost differences with PA (medication costs + PA administration)
and without PA (medication costs only). Model inputs included
CC prevalence estimates from the literature; lubiprostone utili-
zation from IMS Health, 2007; average PA approval rate, PA
costs and co-payment from managed care interviews; and lubi-
prostone wholesale acquisition costs. Annual medication costs in
both scenarios included costs and utilization of lubiprostone less
co-payment, assuming third-tier placement for lubiprostone. All
previously rejected prescriptions were assumed to be accepted
after lifting PA, resulting in 11.36% increase in prescription
volume. Sensitivity analyses were performed on cost per PA, PA
approval rate, and expected increase in prescription volume
after lifting PA. RESULTS: CC prevalence was 14.7%, of which
1.14% were lubiprostone users. For a 1-million member plan,
this resulted in 1264 PA requests costing $27 each. Annual cost
of PA administration was $34,130. PA acceptance rate was
81.90% (or 1035 approved users). Average number of ﬁlls per
person per year was 3.8. A 30-day lubiprostone prescription
costed $43.40 ($86.40 WAC-$45 co-payment + $2 dispensing
fee). Drug costs were $170,737, resulting in total annual cost
with PA of $204,867. Total costs without PA were $190,125,
based on additional 118 approved users, resulting in annual
savings of $14,742. Sensitivity analyses indicated break even
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